Cobalis PreHistin™ to be Granted European Union Patent
10/27/05
Cobalis PreHistin™ Significantly Reduces Allergy Symptoms In 714 Patient Phase III Clinical Trial
09/22/05
Legal Opinion Reinforces Cobalis Patent
03/30/05
Cobalis Appoints Cappello Capital Corp. as Exclusive Strategic Advisor and Investment Banker
03/22/05
Cobalis Signs Agreement With Trendtrade International to Commence Marketing of PreHistin™ in Australia
01/27/05
Cobalis Corp. Completes First Phase III Clinical Study With 715 Patients
IMPORTANT NOTICE: The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.